Acrux

"We conduct a range of transactions involving intellectual property from around the world. Geography is always a challenge because potential buyers of our IP are usually overseas.

We share highly confidential, market sensitive clinical results which cannot be allowed to be altered or falsified in any way – so security is our number one priority. ansarada offers the highest level of security controls to ensure compliance.

With Ansarada we upload confidential documents and give interested parties access to them anywhere in the world, via a web browser.

The platform strengthens the relationships we have with our potential overseas buyers of our clinical data by giving them the freedom to do everything from their desk, in their own time, without having to travel.

I have gotten incredibly positive feedback from possible buyers on ansarada, who have commented that it was very easy to use, quick and accessible.”

Director, Acrux

An agreement for up to $US335 million plus royalties with Eli Lilly (NYSE: LLY) as the worldwide exclusive licensing partner for Axiron™, indicated for the treatment of testosterone deficiency (hypogonadism) in men.